BIOMAT Database Logo BIOMAT Database Logo

Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms. 2019

Jana L Jacobs, and Elias K Halvas, and Melissa A Tosiano, and John W Mellors
Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

HIV-1 viremia persists at low-levels despite clinically effective antiretroviral therapy (ART). Here we review new methods to quantify and characterize persistent viremia at the single genome level, and discuss the mechanisms of persistence including clonal expansion of infected cells and tissue origins of viremia. A deeper understanding of how viremia persists on ART is critically important to the design of therapies to eliminate viremia and achieve a functional cure for HIV-1.

UI MeSH Term Description Entries

Related Publications

Jana L Jacobs, and Elias K Halvas, and Melissa A Tosiano, and John W Mellors
Automated Multireplicate Quantification of Persistent HIV-1 Viremia in Individuals on Antiretroviral Therapy.
November 2020, Journal of clinical microbiology,
Jana L Jacobs, and Elias K Halvas, and Melissa A Tosiano, and John W Mellors
Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy.
November 2014, Journal of clinical microbiology,
Jana L Jacobs, and Elias K Halvas, and Melissa A Tosiano, and John W Mellors
Persistent HIV-1 replication during antiretroviral therapy.
July 2016, Current opinion in HIV and AIDS,
Jana L Jacobs, and Elias K Halvas, and Melissa A Tosiano, and John W Mellors
A Simpler and More Sensitive Single-Copy HIV-1 RNA Assay for Quantification of Persistent HIV-1 Viremia in Individuals on Suppressive Antiretroviral Therapy.
March 2019, Journal of clinical microbiology,
Jana L Jacobs, and Elias K Halvas, and Melissa A Tosiano, and John W Mellors
Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.
August 2011, The Journal of infectious diseases,
Jana L Jacobs, and Elias K Halvas, and Melissa A Tosiano, and John W Mellors
Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: A prospective cohort study.
March 2022, HIV medicine,
Jana L Jacobs, and Elias K Halvas, and Melissa A Tosiano, and John W Mellors
HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.
October 2009, PloS one,
Jana L Jacobs, and Elias K Halvas, and Melissa A Tosiano, and John W Mellors
Learning from Persistent Viremia: Mechanisms and Implications for Clinical Care and HIV-1 Cure.
December 2023, Current HIV/AIDS reports,
Jana L Jacobs, and Elias K Halvas, and Melissa A Tosiano, and John W Mellors
HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia.
September 2005, Journal of acquired immune deficiency syndromes (1999),
Jana L Jacobs, and Elias K Halvas, and Melissa A Tosiano, and John W Mellors
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.
February 2008, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!